American Journal of Kidney Diseases
Volume 51, Issue 5 , Pages 732-740 , May 2008

Metabolic Syndrome, Proteinuria, and the Risk of Progressive CKD in Hypertensive African Americans

  • Janice Lea, MD, MSc

      Affiliations

    • Emory University, Atlanta, GA
    • Corresponding Author InformationAddress correspondence to Janice Lea, MD, Emory University, 101 Woodruff Circle, WMB Rm 338, Atlanta, GA 30322.
    • ,
  • Deanna Cheek, MD

      Affiliations

    • Medical University of South Carolina, Charleston, SC
    • ,
  • Denise Thornley-Brown, MD

      Affiliations

    • University of Alabama, Birmingham, AL
    • ,
  • Lawrence Appel, MD

      Affiliations

    • Johns Hopkins University, Baltimore, MD
    • ,
  • Lawrence Agodoa, MD

      Affiliations

    • National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD
    • ,
  • Gabriel Contreras, MD

      Affiliations

    • University of Miami, Coral Gables, FL
    • ,
  • Jennifer Gassman, PhD

      Affiliations

    • Cleveland Clinic Foundation, Cleveland, OH
    • ,
  • Jim Lash, MD

      Affiliations

    • University of Illinois, Chicago, IL
    • ,
  • Edgar R. Miller III, MD, PhD

      Affiliations

    • Johns Hopkins University, Baltimore, MD
    • ,
  • Otelio Randall, MD

      Affiliations

    • Howard University, Washington, DC.
    • ,
  • Xuelei Wang, MS

      Affiliations

    • Cleveland Clinic Foundation, Cleveland, OH
    • ,
  • William McClellan, MD, MPH

      Affiliations

    • Emory University, Atlanta, GA
    • ,
  • AASK Study Investigators

Received 29 June 2007 ,Accepted 17 January 2008.

References 

  1. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis. 2003;41:1–12
  2. US Renal Data System. USRDS 2003 Annual Data Report. Bethesda, MD: The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2003;
  3. Hunsicker LG, Adler S, Caggiula A, et al. Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study. Kidney Int. 1997;51:1908–1919
  4. Lea J, Greene T, Hebert L, et al. The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: Results of the African American Study of Kidney Disease and Hypertension. Arch Intern Med. 2005;165:947–953
  5. Hsu CY, Lin F, Vittinghoff E, Shlipak MG. Racial differences in the progression from chronic renal insufficiency to end-stage renal disease in the United States. J Am Soc Nephrol. 2003;14:2902–2907
  6. Chen J, Muntner P, Hamm LL, et al. Insulin resistance and risk of chronic kidney disease in nondiabetic US adults. J Am Soc Nephrol. 2003;14:469–477
  7. Chen J, Muntner P, Hamm LL, et al. The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med. 2004;140:167–174
  8. Kurella M, Lo JC, Chertow GM. Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. J Am Soc Nephrol. 2005;16:2134–2140
  9. Agodoa LY, Appel L, Bakris GL, et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: A randomized controlled trial. JAMA. 2001;285:2719–2728
  10. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: Findings from the Third National Health and Nutrition Examination Survey. JAMA. 2002;287:356–359
  11. Peterson JC, Adler S, Burkart JM, et al. Blood pressure control, proteinuria, and the progression of renal disease (The Modification of Diet in Renal Disease Study). Ann Intern Med. 1995;123:754–762
  12. Klag MJ, Whelton PK, Randall BL, et al. Blood pressure and end-stage renal disease in men. N Engl J Med. 1996;334:13–18
  13. Cooper ME. Pathogenesis, prevention, and treatment of diabetic nephropathy. Lancet. 1998;352:213–219
  14. Verani RR. Obesity-associated focal segmental glomerulosclerosis: Pathological features of the lesion and relationship with cardiomegaly and hyperlipidemia. Am J Kidney Dis. 1992;20:629–634
  15. Bagby SP. Obesity-initiated metabolic syndrome and the kidney: A recipe for chronic kidney disease?. J Am Soc Nephrol. 2004;15:2775–2791
  16. Gelber RP, Kurth T, Kausz AT, et al. Association between body mass index and CKD in apparently healthy men. Am J Kidney Dis. 2005;46:871–880
  17. Hsu CY, McCulloch CE, Iribarren C, Darbinian J, Go AS. Body mass index and risk for end-stage renal disease. Ann Intern Med. 2006;144:21–28
  18. Walker WG. Relation of lipid abnormalities to progression of renal damage in essential hypertension, insulin-dependent and non insulin-dependent diabetes mellitus. Miner Electrolyte Metab. 1993;19:137–143
  19. Samuelsson O, Aurell M, Knight-Gibson C, Alaupovic P, Attman PO. Apolipoprotein-B-containing lipoproteins and the progression of renal insufficiency. Nephron. 1993;63:279–285
  20. Fried LF, Orchard TJ, Kasiske BL. Effect of lipid reduction on the progression of renal disease: A meta-analysis. Kidney Int. 2001;59:260–269
  21. Palaniappan L, Carnethon M, Fortmann SP. Association between microalbuminuria and the metabolic syndrome: NHANES III. Am J Hypertens. 2003;16:952–958
  22. Sowers JR. Effects of ACE inhibitors and calcium channel blockers on insulin sensitivity and other components of the syndrome. Nephrol Dial Transplant. 1995;10(suppl 9):S52–S55
  23. Kovacic D, Marinsek M, Gobec L, Lainscak M, Podbregar M. Effect of selective and non-selective beta-blockers on body weight, insulin resistance and leptin concentration in chronic heart failure. Clin Res Cardiol. 2008;97:24–31
  24. Jacob S, Balletshofer B, Henriksen EJ, et al. Beta-blocking agents in patients with insulin resistance: Effects of vasodilating beta-blockers. Blood Press. 1999;8:261–268
  25. Alberti KG, Zimmer PZ. Definition, diagnosis and classification of diabetes mellitus and its complications: Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998;15:539–553
  26. Ford ES, Giles WH. A comparison of the prevalence of the metabolic syndrome using two proposed definitions. Diabetes Care. 2003;26:575–581
  27. Reaven GM, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities—The role of insulin resistance and the sympathoadrenal system. N Engl J Med. 1996;334:374–381

 Originally published online as doi:10.1053/j.ajkd.2008.01.013 on March 13, 2008.

PII: S0272-6386(08)00065-6

doi: 10.1053/j.ajkd.2008.01.013

American Journal of Kidney Diseases
Volume 51, Issue 5 , Pages 732-740 , May 2008

Article Tools

* Image Usage & Resolution